eFFECTOR Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
eFFECTOR Therapeutics, Inc. carries a market capitalization of 2,822.00, placing it among publicly traded companies globally. Its enterprise value stands at -5.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2,822.00 |
| Enterprise Value | -5.13M |
Share Statistics
eFFECTOR Therapeutics, Inc. currently has 3.90M shares outstanding.
| Shares Outstanding | 3.90M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
eFFECTOR Therapeutics, Inc. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2,448.37, indicating elevated leverage, while an interest coverage ratio of -10.94 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.03 |
| Quick Ratio | 0.99 |
| Debt / Equity | 2,448.37 |
| Debt / EBITDA | -0.62 |
| Interest Coverage | -10.94 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -141.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
eFFECTOR Therapeutics, Inc.'s stock has declined approximately -0.00000467% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.00000467% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -32.59M, while operating income came in at -32.70M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -32.70M |
| Pretax Income | -34.63M |
| Net Income | -34.63M |
| EBITDA | -32.59M |
| EBIT | -32.70M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
eFFECTOR Therapeutics, Inc. holds 25.38M in cash and equivalents against 20.25M in total debt, resulting in a net debt position of 4.51M. Total book value stands at -188.21M, with working capital of 681,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 25.38M |
| Total Debt | 20.25M |
| Net Debt | 4.51M |
| Equity (Book Value) | -188.21M |
| Book Value Per Share | N/A |
| Working Capital | 681,000.00 |
Cash Flow
eFFECTOR Therapeutics, Inc. produced -29.19M in operating cash flow over the past twelve months.
| Operating Cash Flow | -29.19M |
| Capital Expenditures | -84,000.00 |
| Free Cash Flow | -29.27M |
| FCF Per Share | N/A |
Scores
eFFECTOR Therapeutics, Inc. posts an Altman Z-Score of -13.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.66 |